Britain should adopt universal hepatitis B immunisation

Britain should adopt universal hepatitis B immunisation, says a senior doctor in this week's BMJ.

The United Kingdom is one of the few developed countries that have not implemented universal immunisation. Because the burden of hepatitis B was low and individual rights were considered paramount, a policy of selective immunisation of high-risk groups, such as health care workers, homosexual men, and drug addicts, has been followed.

However, this approach has failed to provide adequate coverage in Britain and should be replaced by universal immunisation, writes Nicholas Beeching of the Royal Liverpool University Hospital.

The hepatitis B virus causes up to a million deaths worldwide every year. In the United Kingdom, 4,500 acute hepatitis B virus infections, 7,500 new cases of chronic infection, and up to 430 cases of hepatitis B related liver cancer are thought to occur, with estimated NHS costs of up to £375m.

The availability of effective and safe vaccines makes primary prevention of hepatitis B an attractive strategy. Universal immunisation has been adopted by over 150 countries, with evidence of effectiveness lasting more than 10 years in preventing infection, carriage, and liver cancer.

In light of this evidence, it is time that Britain's policy was reviewed, he concludes.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Overtreatment of older men with prostate cancer raises concerns